Mobile phone and laptop displaying data analytics dashboards over a digital background with hexagonal molecular structures and binary code, symbolizing healthcare technology and data analysis.

Digitally Empower Your Nebulized Therapy

From Clinical Trials to Market Success

Generate objective data in clinical trials

Inhaled therapies demand more than just efficacy – they require precision in how treatments are administered. PARI Connect helps you move beyond assumptions by delivering objective, high-quality data that is independent of patient-reported input. The platform documents inhalation behavior and adherence in real time, giving you the transparency to detect deviations early and intervene where necessary. This reduces variability, improves protocol compliance, and strengthens the validity of your clinical outcomes – laying a robust foundation for regulatory approval and market success. 

Mitigate Risk and Strengthen Your Study Outcomes 

  • Increase the statistical power of your clinical trial by gaining objective high-quality data and reducing patient related variability  
  • Avoid misleading data caused by low adherence that could mask efficacy and safety signals 
  • Enable early intervention through remote monitoring 

Enable Long-Term Success during Commercialization  

Sustain Market Penetration with Smart Patient Engagement and Support 

 
Once your product enters the market, the PARI Connect Platform continues to deliver value by helping you retain patients and drive better outcomes: 

  • Empower patients daily with personalized treatment plans and real-time data sharing with healthcare professionals 
  • Enable efficient patient support with visibility into inhalation behavior and targeted digital education 
  • Potential to improve therapy adherence was shown in studies1
  • Enable sustainable business with better therapy outcome and potentially increased prescriptions 
  • Differentiate your product with a white-label app that reflects your branding and delivers cutting-edge patient experience 

~30% higher adherence compared to control group

1Thee S, Inhalation does matter: ConneCT CF – Coaching und Telemonitoring für Patienten mit Cystischer Fibrose, Klin Padiatr 2025; 237(02): S10-S11.

State-of-the-Art eHealth Solutions to Unlock the Full Potential of Your Nebulized Formulation.  

Proven in multiple countries, the PARI Connect Platform offers both objective and reliable data in the clinical phase and adherence optimization in real life during the commercial phase.  

Get in touch to discuss how PARI Connect can become a strategic asset in your development pipeline

eFlow-partneringpari.com

PARI Business Development Team